Enprostil
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Enprostil
| |
| Systematic (IUPAC) name | |
| Methyl 7-[(1R,2R,3R)- 3-hydroxy-2-[(1E,3R)- 3-hydroxy-4-phenoxy-1-butenyl]-5-oxocyclopentyl]- 4,5-heptadienoate | |
| Identifiers | |
| CAS number | |
| ATC code | A02 |
| PubChem | |
| Chemical data | |
| Formula | C23H28O6 |
| Mol. mass | 400.46 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Enprostil | |
|
Articles | |
|---|---|
|
Most recent articles on Enprostil | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Enprostil at Clinical Trials.gov Clinical Trials on Enprostil at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Enprostil
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Enprostil Discussion groups on Enprostil Directions to Hospitals Treating Enprostil Risk calculators and risk factors for Enprostil
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Enprostil | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Enprostil is a synthetic prostaglandin designed to resemble dinoprostone.
It is classified by the World Health Organization under "A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease."
External links
- Toshina K, Hirata I, Maemura K, Sasaki S, Murano M, Nitta M, Yamauchi H, Nishikawa T, Hamamoto N, Katsu K (2000). "Enprostil, a prostaglandin-E(2) analogue, inhibits interleukin-8 production of human colonic epithelial cell lines.". Scand J Immunol 52 (6): 570-5. PMID 11119262.
- Tari A, Hamada M, Kamiyasu T, Sumii K, Haruma K, Inoue M, Kishimoto S, Kajiyama G, Walsh J (1997). "Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients.". Dig Dis Sci 42 (8): 1741-6. PMID 9286243.
- Ching C, Lam S (1995). "A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease.". J Gastroenterol 30 (5): 607-14. PMID 8574332.
Drugs for acid related disorders: Drugs for peptic ulcer and GERD/GORD (A02B) | |
|---|---|
| H2 antagonists | Cimetidine, Famotidine, Nizatidine, Ranitidine, Roxatidine |
| Prostaglandins/analogues | Misoprostol, Enprostil |
| Proton pump inhibitors | Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole, Tenatoprazole |
| Other | Carbenoxolone, Sucralfate, Pirenzepine |
Eicosanoids: prostaglandins | |
|---|---|
| Endogenous/series 2 | D2 - E2 (Dinoprostone) - F2 (Dinoprost) - H2 - I2 (Prostacyclin) |
| Prostaglandin analogues | E: Alprostadil - Enprostil - Misoprostol
F: Bimatoprost - Carboprost - Latanoprost - Travoprost I: Beraprost - Iloprost - Treprostinil |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
